Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 62

  • 22

  • 8

  • 7

  • 7

  • 6

  • 6

  • 5

  • 4

  • 3

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer

Funder: National Cancer Institute

Funding period
USD 300 K
Funding amount
Abstract
Project Summary/Abstract Bladder cancer causes over 165,000 annual deaths worldwide with 70,000 new cases and 16,000 deaths reported in the US. Treatment of superficial bladder cancer by resection and BCG administration is unsuccessful in 40% of cases with recurrences eventually requiring cystectomy or other aggressive therapy; new therapies are needed. The role of Epidermal Growth Factor Receptor (EGFR) in bladder cancer pathogenesis has been well established and its pathologic expression on the luminal side of uroepithelial cells in 70% of patients provides an ideal target for intravesical targeted therapy. We have previously demonstrated DTEGF?a single chain protein, encoding modified diphtheria toxin (DT) that has replaced the B-chain sequence normally enabling cell entry with that of Epidermal Growth Factor?was efficacious in a syngeneic rodent model of bladder cancer, as well as in a number of xenograph explants of human bladder cancer in nude mice. Toxicity was not observed in these murine studies, nor in a pilot study in dogs demonstrated intravesical DTEGF was well tolerated at concentrations well above those needed for efficacy. IND-enabling studies are needed for DTEGF to move into the clinical testing. While we have preclinical proof-of-concept with DTEGF, another company has demonstrated Phase II clinical proof-of-concept with an EpCAM-toxinA fusion- toxin demonstrating 40% complete response in superficial bladder cancer patients. Their work provides a proven developmental path for our EGFR targeted toxin. The present grant application proposes to optimize intravesical administration and subsequently complete IND-enabling safety studies, hold a pre-IND meeting and complete an IND application. Completion of this work would position our agent as one with a very high likelihood success to be ready for clinically testing. We anticipate DTEGF to address the unmet need of patients that fail BCG (40%) and over express EGFR (70%) and eventually become a first line therapy that will likely work with EpCAM-targeted and other therapies to benefit the majority of patients.

 
156
Projects
USD 69.1 M
Aggregated funding amount
USD 474 K
Average funding amount
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 203,510
2019 - 2021
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 656,816
2019 - 2024
Project list item
Novel recombinant BCG for immunotherapy of bladder cancer

National Cancer Institute to BORIS SHOR

USD 290,014
2018 - 2019
Project list item
Intra-operative MRI-guided Robotic System for Photothermal Therapy of Bladder Cancer

University Grants Committee to Kwok Ka Wai, Wong Kenneth Kin Yip, Vardhanabhuti Varut Vince, TEOH Yuen Chun Jeremy

USD 80,682
2018 - 2021
Project list item
Ty21a immunotherapy of non-muscle-invasive bladder cancer

Swiss National Science Foundation to Denise Nardelli Haefliger, Mathieu Chevalier, Patrice Jichlinski, Lenka Chalupova

USD 436,670
2018 - 2021
Project list item
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Patient-Centered Outcomes Research Institute to John Gore

USD 8,500,000
2018 - 2022
Project list item
INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCER

National Cancer Institute to ROSA MARIA DIAZ, BRADLEY C. LEIBOVICH, LUKKANA SUKSANPAISAN

USD 1,081,593
2017 - 2020
Project list item
Multi-Antigen Vaccines for the Primary and Secondary Prevention of Bladder CancerTO POP: 9/15/2017 - 3/14/2019

National Cancer Institute to CLINTON GRUBBS

USD 636,313
2017 - 2019
Project list item
The Role of EZH2 in Non-Muscle Invasive Bladder Cancer

United States Department of Veterans Affairs to JOSHUA JAMES MEEKS

 
2016 - 2020
Project list item
Investigation of Genetic and Immune Mechanisms of Response to BCG for Non-Muscle Invasive Bladder Cancer: A Translational Study of S1602

Congressionally Directed Medical Research Programs to Joshua J Meeks

USD 661,890
2016 - 2017
Project list item
Investigation of Genetic and Immune Mechanisms of Response to BCG for Non-Muscle Invasive Bladder Cancer: A Translational Study of S1602

Congressionally Directed Medical Research Programs to Robert Svatek

USD 428,545
2016 - 2017
Project list item
Investigation of Genetic and Immune Mechanisms of Response to BCG for Non-Muscle Invasive Bladder Cancer: A Translational Study of S1602

Congressionally Directed Medical Research Programs to David Mcconkey

USD 437,139
2016 - 2017
Project list item
Understanding barriers to single-dose intravesical chemotherapy in non-muscle invasive bladder cancer

National Cancer Institute to KELLY CLINTON CARY

USD 433,019
2016 - 2021
Project list item
Sh3gl2 and chemosensitivity of bladder cancer

National Cancer Institute to ROSALYN M ADAM

USD 492,035
2016 - 2019
Project list item
Regulation of ATDC by TP63 and its role in bladder cancer

National Cancer Institute to PHILLIP L PALMBOS

USD 524,880
2016 - 2021
Project list item
Pluripotent stem cell-derived bladder epithelial progenitors for definitive cell replacement therapy of bladder cancer

California Institute for Regenerative Medicine to Philip Beachy

USD 1,400,033
2016 - 2016
Project list item
Role of antigen-specific immunity in BCG therapy for bladder cancer

Bladder Cancer Advocacy Network to Niannian Ji, Robert Scott Svatek

USD 50,000
2016 - 2018
Project list item
Bladder Fiducial Markers and Diffusion-MRI to Optimize Bladder Chemo-Radiotherapy

National Cancer Institute to MAURICE MARCEL GARCIA

USD 1,574,130
2016 - 2022
load more...